Nalmefene for reducing alcohol consumption in people with alcohol dependence

  • Technology appraisal guidance
  • TA325
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research:

  • Stevenson M, Pandor A, Stevens J, Rawdin A, Wong R, Morgan MY, Rice P, Thompson J. Nalmefene for reducing alcohol consumption in people with alcohol dependence: A Single Technology Appraisal. School of Health and Related Research (ScHARR), 2014.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company/sponsor:

  • Lundbeck

II. Professional/expert and patient/carer groups:

  • ADFAM

  • Alcohol Concern

  • British Liver Trust

  • Lifeline Project

  • British Association for Psychopharmacology

  • National Substance Misuse Non‑Medical Prescribing Forum

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal College of Psychiatrists

III. Other consultees:

  • Department of Health

  • NHS England

  • NHS Stafford and Surrounds CCG

  • NHS Warrington CCG

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Association of Directors of Public Health

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • Social Care Institute for Excellence

  • Bristol‑Myers Squibb Pharmaceuticals

  • Institute of Alcohol Study

  • School of Health and Related Research

  • National Institute for Health Research Health Technology Assessment Programme

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on nalmefene by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Chris Daly, Lead Consultant Addiction Psychiatrist, nominated by the Royal College of Psychiatrists – clinical expert

  • Simon Greasley, Specialist Nurse Practitioner, nominated by the Royal College of Nursing – clinical expert

  • Andrew Langford, nominated by British Liver Trust – patient expert

  • Oliver Standing, nominated by ADFAM– patient expert

E. Representatives from the following company/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Lundbeck